Genmab — September 2017
-
Nej

-
Ja mon ikke vi får en dejlig Q4 i Gen

-
Udrulningen fra J&J brager derudad.
-
Herligt at være aktionær i Altai i den seneste måned

-
Forkert chat
-
An investigationel immuno- therapy study to investigate the safety and effectiveness of Nivolumab and Nivolumab combination therapy in virus- associated tumors ( CheckMate 358 ) opdateret 28-09-2017. https://www.clinicaltrials.gov/ct2/show/NCT02488759?term=Darzalex&recrs=ab&cond=Solid+Tumor&rank=2
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind